Eight Myopia Mysteries (plus eight more!)

This open-access continuing education article I authored was published in Australian professional journal Mivision in December 2018. It describes that while there’s a lot we know about myopia control – the imperative to reduce lifelong risk of vision impairment; that numerous options are available; and that the sooner we start the better – it is imperative for the clinician to …

Read MoreEight Myopia Mysteries (plus eight more!)

Atropine – wonder or weak treatment?

Atropine has been the apparent hero of myopia management since the 2006 publication of the ATOM (atropine for the treatment of childhood myopia) study, which showed an 80% refractive and 100% axial length myopia controlling effect with 1% atropine compared to placebo.1 The significant side effects of mydriasis and cycloplegia, though, made it less than tolerable as a first line …

Read MoreAtropine – wonder or weak treatment?

Latest research: International Myopia Conference 2017, Part 2

More of the latest from the sixteenth biennial International Myopia Conference (IMC) is below – read here for Part 1. Three more fascinating areas and/or pieces of research presented at IMC, and some bonus material, are below. A more detailed write up, published in Australian industry journal Mivision, can be accessed from the link, which includes relevant references. IMC #4 – …

Read MoreLatest research: International Myopia Conference 2017, Part 2

Atropine for myopia control – the clinical experience

In 2010 Visique Rose Optometrists in New Zealand launched its myopia control clinic. The aim of this clinic was to provide evidence based treatment options for the correction for myopia. Two years ago Atropine was introduced with help and collaboration of local ophthalmology. All patients within the clinic are reviewed regularly with cycloplegic refraction (as indicated) and IOL master measurement …

Read MoreAtropine for myopia control – the clinical experience